Arun Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arun Sharma has a total of 417 co-authors. Here are the top co-authors by number of shared publications:
- Joseph C. Wu
Stanford Cardiovascular Institute and
12 shared publications - Sean M. Wu
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305
12 shared publications Haodi Wu
Stanford Cardiovascular Institute, Stanford University School of Medicine, 265 Campus Drive, Room G1120B, Stanford, CA 94305, USA
10 shared publicationsMadelyn Arzt
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
9 shared publicationsMaedeh Mozneb
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
8 shared publicationsPaul W. Burridge
Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Center for Pharmacogenomics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
8 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Elsevier in Stem Cell Reports
- Vol. 21 (11)
What impact has iPSC technology had on your research and/or field?
- 10 November 2026
- Published by Elsevier in Stem Cell Reports
- Vol. 21 (11)
Open AccessWhat impact has iPSC technology had on your research and/or field?
- Open Access
Expanded Proteome Coverage Powered by Advanced Ion Processing Enables Deep Single-Cell Drug Response Subtyping in Human Stem Cell Derived Cardiomyocytes
Single-cell proteomics (SCP) enables the study of cellular heterogeneity at the functional level but remains limited by incomplete proteome coverage and high data missingness. Here, we present an enhanced label-free SCP workflow that leverages the timsUltra AIP mass spectrometry platform equipped with the Athena Ion Processor (AIP). Across a controlled dilution series of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), AIP-enabled acquisition consistently increased proteome depth and detection consistency across cells at all input levels. In single iPSC-CMs, the timsUltra AIP quantified up to 3,858 protein groups, averaging ~1,300 proteins per cell, enabling robust proteome-level classification of cardiomyocyte subtypes. Using a reference-based protein classifier, cells were stratified into mature cardiomyocytes and less differentiated cell states, revealing substantial baseline heterogeneity. Importantly, increased single-cell sensitivity translated directly into biological insight, as approximately 30% of differentially expressed proteins associated with subtype-specific drug responses were detected exclusively by timsUltra AIP. Application of this workflow to PR-364 (a mitophagy boosting drug) dose-response experiment uncovered distinct, subtype-dependent pathway adaptations. Mature cardiomyocytes exhibited dose-dependent increases in mitochondrial and metabolic pathway activity, while immature cells showed enrichment of cytoskeletal and developmental programs. These effects were partially obscured in simulated bulk analyses, highlighting the value of single-cell resolution. Together, these results demonstrate that improved fragment ion transmission and utilization translate directly into enhanced biological insight, enabling more comprehensive and functionally relevant single-cell proteomics.
Open AccessExpanded Proteome Coverage Powered by Advanced Ion Processing Enables Deep Single-Cell Drug Response Subtyping in Human Stem Cell Derived Cardiomyocytes
Single-cell proteomics (SCP) enables the study of cellular heterogeneity at the functional level but remains limited by incomplete proteome coverage and high data missingness. Here, we present an enhanced label-free SCP workflow that leverages the timsUltra AIP mass spectrometry platform equipped with the Athena Ion Processor (AIP). Across a controlled dilution series of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), AIP-enabled acquisition consistently increased proteome depth and detection consistency across cells at all input levels. In single iPSC-CMs, the timsUltra AIP quantified up to 3,858 protein groups, averaging ~1,300 proteins per cell, enabling robust proteome-level classification of cardiomyocyte subtypes. Using a reference-based protein classifier, cells were stratified into mature cardiomyocytes and less differentiated cell states, revealing substantial baseline heterogeneity. Importantly, increased single-cell sensitivity translated directly into biological insight, as approximately 30% of differentially expressed proteins associated with subtype-specific drug responses were detected exclusively by timsUltra AIP. Application of this workflow to PR-364 (a mitophagy boosting drug) dose-response experiment uncovered distinct, subtype-dependent pathway adaptations. Mature cardiomyocytes exhibited dose-dependent increases in mitochondrial and metabolic pathway activity, while immature cells showed enrichment of cytoskeletal and developmental programs. These effects were partially obscured in simulated bulk analyses, highlighting the value of single-cell resolution. Together, these results demonstrate that improved fragment ion transmission and utilization translate directly into enhanced biological insight, enabling more comprehensive and functionally relevant single-cell proteomics.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e004918
ROBO2 Variants Associated With Atrial Septal Defect Define a Novel Regulatory Element
BACKGROUND: Atrial septal defects (ASDs) are a prevalent type of congenital heart disease. Previous GWAS (Genome-Wide Association Studies) have identified common variants associated with ASDs, though their mechanisms remain unknown. We aimed to expand insights into the architecture of common variants associated with ASD risk and elucidate functional mechanisms. METHODS: We conducted a GWAS using isolated ASD cases and healthy controls and replicated findings in an independent cohort. We examined epigenetic marks within this ASD locus in human induced pluripotent stem cell-derived cardiomyocytes and fetal human hearts. We characterized the consequences of deletions introduced by CRISPR-Cas9 mutagenesis of human induced pluripotent stem cells to assess the effect on downstream gene expression. In addition, we investigated the 3-dimensional genome architecture of the locus using chromosome conformation capture sequencing. RESULTS: We identified a novel ASD locus on chromosome 3p12.3 encompassing the ROBO2 gene, which encodes the Roundabout guidance receptor 2 for Slit ligands. This locus includes 15 common single nucleotide polymorphisms, an enhancer, and a CCCTC-binding factor (CTCF)-binding site. Deletions of varying lengths within the ASD-associated locus in human induced pluripotent stem cell-derived cardiomyocytes reduced ROBO2 expression and dysregulated the expression of extracellular matrix genes. Chromosome conformation capture sequencing indicated that this region physically interacts with the ROBO2 promoter and demonstrates that the CTCF-binding site is essential for this contact. CONCLUSIONS: Novel common single nucleotide polymorphisms in regulatory elements controlling ROBO2 transcription contribute to risk for ASDs. These data infer key roles for the Roundabout guidance receptor 2 and Slit ligands in embryogenic development and maturation of the atrial septa.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e004918
ROBO2 Variants Associated With Atrial Septal Defect Define a Novel Regulatory Element
BACKGROUND: Atrial septal defects (ASDs) are a prevalent type of congenital heart disease. Previous GWAS (Genome-Wide Association Studies) have identified common variants associated with ASDs, though their mechanisms remain unknown. We aimed to expand insights into the architecture of common variants associated with ASD risk and elucidate functional mechanisms. METHODS: We conducted a GWAS using isolated ASD cases and healthy controls and replicated findings in an independent cohort. We examined epigenetic marks within this ASD locus in human induced pluripotent stem cell-derived cardiomyocytes and fetal human hearts. We characterized the consequences of deletions introduced by CRISPR-Cas9 mutagenesis of human induced pluripotent stem cells to assess the effect on downstream gene expression. In addition, we investigated the 3-dimensional genome architecture of the locus using chromosome conformation capture sequencing. RESULTS: We identified a novel ASD locus on chromosome 3p12.3 encompassing the ROBO2 gene, which encodes the Roundabout guidance receptor 2 for Slit ligands. This locus includes 15 common single nucleotide polymorphisms, an enhancer, and a CCCTC-binding factor (CTCF)-binding site. Deletions of varying lengths within the ASD-associated locus in human induced pluripotent stem cell-derived cardiomyocytes reduced ROBO2 expression and dysregulated the expression of extracellular matrix genes. Chromosome conformation capture sequencing indicated that this region physically interacts with the ROBO2 promoter and demonstrates that the CTCF-binding site is essential for this contact. CONCLUSIONS: Novel common single nucleotide polymorphisms in regulatory elements controlling ROBO2 transcription contribute to risk for ASDs. These data infer key roles for the Roundabout guidance receptor 2 and Slit ligands in embryogenic development and maturation of the atrial septa.
- Open Access
- 4 October 2025
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (10) , 1491-1508
Stem cell research in space: Advancing regenerative medicine beyond Earth
- 4 October 2025
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (10) , 1491-1508
Open AccessStem cell research in space: Advancing regenerative medicine beyond Earth
- 5 September 2025
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 32 (3) , 256-268
Human cardiac organoids for disease modeling and drug discovery
- 5 September 2025
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 32 (3) , 256-268
Human cardiac organoids for disease modeling and drug discovery
- Open Access
- 16 June 2025
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 27 (1) , 1-7
Regenerative Medicine Approaches to Address Cardiovascular Issues During Spaceflight
Purpose of Review: Spaceflight exposes astronauts to unique physiological stressors, with microgravity and weightlessness significantly impacting the human body. The cardiovascular system undergoes profound alterations, including cardiac atrophy, vascular remodeling, and arrhythmias, posing risks for long-duration missions. Recent Findings: With a significant shift in biomedical research towards stem cell research and their derivatives, these cells exhibit potential for modeling and mitigating human diseases while enhancing translational potential. Using human induced pluripotent stem cells (hiPSCs) in space offers a promising avenue for personalized regenerative medicine, leveraging microgravity to enhance stem cell proliferation, differentiation, and tissue engineering. Summary: By integrating stem cell biology with space-based biotechnologies, researchers can accelerate the discovery of precision medicine approaches. Biomanufacturing in space further enables disease modeling of aging-related diseases in particular by mimicking accelerated aging phenotypes in a controlled environment. These advancements not only address astronaut health challenges but also may translate to novel treatment options for cardiovascular and degenerative diseases on Earth.
- 16 June 2025
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 27 (1) , 1-7
Open AccessRegenerative Medicine Approaches to Address Cardiovascular Issues During Spaceflight
Purpose of Review: Spaceflight exposes astronauts to unique physiological stressors, with microgravity and weightlessness significantly impacting the human body. The cardiovascular system undergoes profound alterations, including cardiac atrophy, vascular remodeling, and arrhythmias, posing risks for long-duration missions. Recent Findings: With a significant shift in biomedical research towards stem cell research and their derivatives, these cells exhibit potential for modeling and mitigating human diseases while enhancing translational potential. Using human induced pluripotent stem cells (hiPSCs) in space offers a promising avenue for personalized regenerative medicine, leveraging microgravity to enhance stem cell proliferation, differentiation, and tissue engineering. Summary: By integrating stem cell biology with space-based biotechnologies, researchers can accelerate the discovery of precision medicine approaches. Biomanufacturing in space further enables disease modeling of aging-related diseases in particular by mimicking accelerated aging phenotypes in a controlled environment. These advancements not only address astronaut health challenges but also may translate to novel treatment options for cardiovascular and degenerative diseases on Earth.
- Open Access
- 28 April 2025
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 11 (1) , 1-8
Human Induced Pluripotent Stem Cells for Advancing Regenerative Medicine in Space
Purpose of Review: Space medicine research investigates the effects of microgravity on physiological systems to improve both astronaut health and develop clinical therapies for patients on Earth. Here, we discuss the benefits and challenges of conducting such studies and examine the role of human induced pluripotent stem cells (hiPSCs) for advancing regenerative and space medicine. Recent Findings: Recent advancements in space medicine research reflect the potential for microgravity to mimic the effects of aging and degenerative diseases at an accelerated pace. hiPSCs address previous ethical concerns with the use of embryonic stem cells while also providing a patient-specific approach to disease modeling and treatment development. Summary: Overall, despite the challenges that come with performing space medicine research, advancements in stem cell technology provide new opportunities for studying biological processes in the unique conditions of space. Future work will focus on refining current techniques and further translating space-based findings into clinical applications.
- 28 April 2025
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 11 (1) , 1-8
Open AccessHuman Induced Pluripotent Stem Cells for Advancing Regenerative Medicine in Space
Purpose of Review: Space medicine research investigates the effects of microgravity on physiological systems to improve both astronaut health and develop clinical therapies for patients on Earth. Here, we discuss the benefits and challenges of conducting such studies and examine the role of human induced pluripotent stem cells (hiPSCs) for advancing regenerative and space medicine. Recent Findings: Recent advancements in space medicine research reflect the potential for microgravity to mimic the effects of aging and degenerative diseases at an accelerated pace. hiPSCs address previous ethical concerns with the use of embryonic stem cells while also providing a patient-specific approach to disease modeling and treatment development. Summary: Overall, despite the challenges that come with performing space medicine research, advancements in stem cell technology provide new opportunities for studying biological processes in the unique conditions of space. Future work will focus on refining current techniques and further translating space-based findings into clinical applications.
- Open Access
- 22 January 2025
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 24 (9) , 100910
Single-Cell Proteomics Reveals Specific Cellular Subtypes in Cardiomyocytes Derived From Human iPSCs and Adult Hearts
- 22 January 2025
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 24 (9) , 100910
Open AccessSingle-Cell Proteomics Reveals Specific Cellular Subtypes in Cardiomyocytes Derived From Human iPSCs and Adult Hearts
- Open Access
- 17 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Regulation of sarcomere formation and function in the healthy heart requires a titin intronic enhancer
Heterozygous truncating variants in the sarcomere protein titin (TTN) are the most common genetic cause of heart failure. To understand mechanisms that regulate abundant cardiomyocyte (CM) TTN expression, we characterized highly conserved intron 1 sequences that exhibited dynamic changes in chromatin accessibility during differentiation of human CMs from induced pluripotent stem cells (hiPSC-CMs). Homozygous deletion of these sequences in mice caused embryonic lethality, whereas heterozygous mice showed an allele-specific reduction in Ttn expression. A 296 bp fragment of this element, denoted E1, was sufficient to drive expression of a reporter gene in hiPSC-CMs. Deletion of E1 downregulated TTN expression, impaired sarcomerogenesis, and decreased contractility in hiPSC-CMs. Site-directed mutagenesis of predicted binding sites of NK2 homeobox 5 (NKX2-5) and myocyte enhancer factor 2 (MEF2) within E1 abolished its transcriptional activity. In embryonic mice expressing E1 reporter gene constructs, we validated in vivo cardiac-specific activity of E1 and the requirement for NKX2-5– and MEF2-binding sequences. Moreover, isogenic hiPSC-CMs containing a rare E1 variant in the predicted MEF2-binding motif that was identified in a patient with unexplained dilated cardiomyopathy (DCM) showed reduced TTN expression. Together, these discoveries define an essential, functional enhancer that regulates TTN expression. Manipulation of this element may advance therapeutic strategies to treat DCM caused by TTN haploinsufficiency.
- 17 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Open AccessRegulation of sarcomere formation and function in the healthy heart requires a titin intronic enhancer
Heterozygous truncating variants in the sarcomere protein titin (TTN) are the most common genetic cause of heart failure. To understand mechanisms that regulate abundant cardiomyocyte (CM) TTN expression, we characterized highly conserved intron 1 sequences that exhibited dynamic changes in chromatin accessibility during differentiation of human CMs from induced pluripotent stem cells (hiPSC-CMs). Homozygous deletion of these sequences in mice caused embryonic lethality, whereas heterozygous mice showed an allele-specific reduction in Ttn expression. A 296 bp fragment of this element, denoted E1, was sufficient to drive expression of a reporter gene in hiPSC-CMs. Deletion of E1 downregulated TTN expression, impaired sarcomerogenesis, and decreased contractility in hiPSC-CMs. Site-directed mutagenesis of predicted binding sites of NK2 homeobox 5 (NKX2-5) and myocyte enhancer factor 2 (MEF2) within E1 abolished its transcriptional activity. In embryonic mice expressing E1 reporter gene constructs, we validated in vivo cardiac-specific activity of E1 and the requirement for NKX2-5– and MEF2-binding sequences. Moreover, isogenic hiPSC-CMs containing a rare E1 variant in the predicted MEF2-binding motif that was identified in a patient with unexplained dilated cardiomyopathy (DCM) showed reduced TTN expression. Together, these discoveries define an essential, functional enhancer that regulates TTN expression. Manipulation of this element may advance therapeutic strategies to treat DCM caused by TTN haploinsufficiency.
- Open Access
- 24 October 2024
- Published by Wiley in Current Protocols
- Vol. 4 (10) , e70030
Recording and Interpretation of Active Calcium Transients in Induced Pluripotent Stem Cell‐Derived Cardiomyocytes
Calcium plays a pivotal role in the excitation‐contraction coupling process in cardiomyocytes, a critical multi‐parametric event leading to rhythmic contraction. Over the past few decades, calcium signaling in cardiomyocytes has been extensively studied in cardiovascular sciences. However, a standard methodology is needed not only to trace the calcium within cells but also to remove signal processing biases and to accurately interpret the features of calcium transient signals in relation to cardiomyocyte electrophysiology. This article outlines the use of genetically encoded calcium indicator (GCaMP) human‐induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs) to record calcium transients. These cells express a green fluorescent signal when calcium binds to intracellular calmodulin, a key regulator of calcium signaling. The extraction and processing of calcium transient waveforms are performed using ImageJ and MATLAB software. Key features of these waveforms are then identified and categorized based on their physiological relevance to cardiomyocyte function. Additionally, this work includes a Support Protocol for the successful replating of cardiomyocytes onto non‐traditional culture platforms, such as metallic sensors and polymer‐based substrates, to facilitate data multiplexing. The three Basic Protocols outlined here provide a comprehensive approach for maintaining, expanding, and differentiating the GCaMP hiPSCs, video recording of calcium transients, and the subsequent signal extraction, preprocessing, analysis, and data visualization. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: Maintenance, expansion, and differentiation of genetically encoded calcium indicator hiPSCsSupport Protocol: Replating GCaMP hiPSC‐CMs for stimulation and multielectrode array studiesBasic Protocol 2: Video recording from calcium transients of GCaMP hiPSC‐CMsBasic Protocol 3: Signal extraction, preprocessing, analysis, and data visualization
- 24 October 2024
- Published by Wiley in Current Protocols
- Vol. 4 (10) , e70030
Open AccessRecording and Interpretation of Active Calcium Transients in Induced Pluripotent Stem Cell‐Derived Cardiomyocytes
Calcium plays a pivotal role in the excitation‐contraction coupling process in cardiomyocytes, a critical multi‐parametric event leading to rhythmic contraction. Over the past few decades, calcium signaling in cardiomyocytes has been extensively studied in cardiovascular sciences. However, a standard methodology is needed not only to trace the calcium within cells but also to remove signal processing biases and to accurately interpret the features of calcium transient signals in relation to cardiomyocyte electrophysiology. This article outlines the use of genetically encoded calcium indicator (GCaMP) human‐induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs) to record calcium transients. These cells express a green fluorescent signal when calcium binds to intracellular calmodulin, a key regulator of calcium signaling. The extraction and processing of calcium transient waveforms are performed using ImageJ and MATLAB software. Key features of these waveforms are then identified and categorized based on their physiological relevance to cardiomyocyte function. Additionally, this work includes a Support Protocol for the successful replating of cardiomyocytes onto non‐traditional culture platforms, such as metallic sensors and polymer‐based substrates, to facilitate data multiplexing. The three Basic Protocols outlined here provide a comprehensive approach for maintaining, expanding, and differentiating the GCaMP hiPSCs, video recording of calcium transients, and the subsequent signal extraction, preprocessing, analysis, and data visualization. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: Maintenance, expansion, and differentiation of genetically encoded calcium indicator hiPSCsSupport Protocol: Replating GCaMP hiPSC‐CMs for stimulation and multielectrode array studiesBasic Protocol 2: Video recording from calcium transients of GCaMP hiPSC‐CMsBasic Protocol 3: Signal extraction, preprocessing, analysis, and data visualization